Maze Therapeutics' CMO Sells Entire Direct Stake for $255K
Harold Bernstein, Chief Medical Officer and President of Research and Development at Maze Therapeutics (MAZE), sold his entire direct stake in the company on September 4, 2026. The transaction involved selling 9,705 shares under a pre-established Rule 10b5-1 trading plan for $255,000 at an average price of $26.22 per share. The sale has raised investor concerns amid the company's recent stock performance decline—down nearly 50% from its March 2026 high of $53.65 to a closing price near $24.82 on September 10, 2026. Despite this liquidation, Bernstein still holds derivative securities in the form of options and restricted stock units. Maze Therapeutics is focused on developing precision medicines for kidney and metabolic diseases with lead programs MZE829 (Phase II) and MZE782 (Phase II-ready). The company has a market cap of $1.5 billion but reported a net loss of $133.6 million in the trailing twelve months.
Tickers: $MAZE
Topics: executive sale Maze Therapeutics Rule 10b5-1 trading plan